Peps
Abaloparatide
Abaloparatide is a bone-forming prescription medicine for osteoporosis. Its clinically relevant outcome is prevention of fractures in appropriately selected patients.
Prescription medicines
Read the risks →Peptides that flag cancer, now or in the past
These 22 profiles mention cancer, now or in the past in their Risks & interactions section, from the FDA label for approved drugs or from published studies for research compounds. Open a profile and read that section to see exactly why.
A peptide that isn't listed may simply have no human safety data, which doesn't make it safe for you. Dashed tags on investigational GLP-1 drugs come from the labels of approved drugs in the same class. Not medical advice: talk to a doctor or pharmacist about your own situation. All peptides · Heart or blood pressure problems · Blood thinners or bleeding problems · Diabetes or blood-sugar medicines · Pregnancy or breastfeeding · Kidney problems · Liver problems
AOD-9604
AOD-9604 is a modified fragment of growth hormone investigated for metabolic effects. Animal experiments and the later human obesity program tell different parts of its story.
Research topics
Read the risks →
Calcitonin salmon
Salmon calcitonin is a hormone medicine that reduces bone breakdown. Injectable and nasal preparations have distinct clinical histories and instructions.
Prescription medicines
Read the risks →
Dulaglutide
Dulaglutide, marketed as Trulicity, is a long-acting GLP-1 receptor agonist used in type 2 diabetes care. Its research includes blood-sugar control and cardiovascular outcomes.
Prescription medicines
Read the risks →
Efpeglenatide
Efpeglenatide is an exendin-based GLP-1 receptor agonist. AMPLITUDE-O examined cardiovascular and kidney outcomes in a high-risk type 2 diabetes population.
Research topics
Read the risks →
Glutathione
Glutathione is an endogenous tripeptide involved in redox biology. A six-month oral-supplement trial measured glutathione stores in several body compartments.
Research topics
Read the risks →
HCG
Human chorionic gonadotropin is a glycoprotein hormone involved in reproductive signaling. The featured study compared hormonal approaches in men with hypogonadism seeking to preserve fertility.
Research topics
Read the risks →
Leuprolide
Leuprolide is a GnRH agonist used to control sex-hormone signaling in several conditions. It belongs to a different pathway from growth-hormone secretagogues.
Prescription medicines
Read the risks →
Liraglutide
Liraglutide is an incretin medicine with distinct diabetes and weight-management product contexts. Its benefits should be tied to the exact indication and population.
Prescription medicines
Read the risks →
Mazdutide
Mazdutide is a dual GLP-1 and glucagon receptor agonist studied for weight management. GLORY-1 tested it in Chinese adults with overweight or obesity.
Research topics
Read the risks →
NAD+
NAD+ is a cofactor involved in cellular redox metabolism. A human pilot measured its metabolic fate during infusion; that experiment did not test longevity, cognition, or treatment of a disease.
Related compounds
Read the risks →
Octreotide
Octreotide is a somatostatin-related medicine used in specialist endocrine and gastrointestinal care. Immediate- and long-acting preparations have different roles.
Prescription medicines
Read the risks →
Pemvidutide
Pemvidutide is a dual GLP-1 and glucagon receptor agonist investigated in metabolic dysfunction-associated steatohepatitis (MASH). Its liver-biopsy outcomes should be separated from weight-loss claims.
Research topics
Read the risks →
Retatrutide
Retatrutide is a triple-receptor agonist investigated for obesity and related metabolic conditions. Its trial identity differs from unverified coded seller listings.
Investigational
Read the risks →
Semaglutide
Semaglutide is an incretin medicine with product-specific uses in diabetes, weight management, and other defined conditions. Brand and formulation matter.
Prescription medicines
Read the risks →
Survodutide
Survodutide is a dual GLP-1 and glucagon receptor agonist. A 2026 phase 3 publication reports weight outcomes in adults with obesity or overweight without diabetes.
Research topics
Read the risks →
Teduglutide
Teduglutide is a peptide medicine for short bowel syndrome with dependence on intravenous nutrition or fluids. It acts in a different pathway from GLP-1 medicines.
Prescription medicines
Read the risks →
Teriparatide
Teriparatide is a parathyroid-hormone-related medicine used in osteoporosis care. Fracture reduction is a more direct clinical outcome than a bone marker alone.
Prescription medicines
Read the risks →
Tesamorelin
Tesamorelin is a prescription peptide for excess abdominal fat in HIV-associated lipodystrophy. It is not a general weight-loss medicine.
Prescription medicines
Read the risks →
Tirzepatide
Tirzepatide is a dual-incretin medicine with distinct product and indication contexts. Its clinical-trial material is not interchangeable with a research-use vial.
Prescription medicines
Read the risks →
TRH (thyrotropin-releasing hormone)
TRH is one of the body's own hormones: a tiny peptide made in the brain that tells the pituitary gland to release thyroid-stimulating hormone. A synthetic version, protirelin, was long used in a hospital test of thyroid and pituitary function. Researchers have also studied it in small trials for fatigue, depression and nerve diseases.
Research topics
Read the risks →
Triptorelin
Triptorelin is a GnRH agonist used for hormone suppression in clinical settings. The featured breast-cancer analysis included several ways of achieving ovarian suppression.
Prescription medicines
Read the risks →See something wrong on this page? Report a mistake · Corrections